Actively Recruiting

Phase Not Applicable
Age: 18Years - 60Years
All Genders
NCT03773523

Neuromodulation and Cognitive Training in Opioid Use Disorder

Led by University of Minnesota · Updated on 2025-06-12

30

Participants Needed

1

Research Sites

354 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The relapsing nature of opioid use disorder is a major obstacle to successful treatment. About 90% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that can modulate brain connectivity.

CONDITIONS

Official Title

Neuromodulation and Cognitive Training in Opioid Use Disorder

Who Can Participate

Age: 18Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 60 years
  • Abstinent from opioid use for 1 to 2 weeks
  • Meet DSM-V criteria for opioid use disorder
  • Ability to provide written consent and comply with study procedures
  • Intend to remain in a 4-week supervised treatment program during the study
  • May have current comorbid drug use but primary diagnosis must be opioid use disorder
  • Recruited from the Lodging Plus Program at University of Minnesota Medical Center
Not Eligible

You will not qualify if you...

  • Medical conditions or treatments causing neurological damage (e.g., stroke, tumor, loss of consciousness over 30 minutes, HIV)
  • Head injury causing skull fracture or loss of consciousness over 30 minutes
  • Contraindications for tDCS or MRI (e.g., history of seizures, metal implants, pacemakers, pregnancy)
  • DSM-V diagnosis of psychiatric disorders except lifetime depression
  • Conditions preventing study measures from being administered or interpreted
  • Age outside 18 to 60 years
  • Primary substance use disorder diagnosis other than opioid (except caffeine or nicotine)
  • Clinical evidence of Wernicke-Korsakoff syndrome
  • Nicotine use will be recorded but not excluded

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Minnesota

Minneapolis, Minnesota, United States, 55414

Actively Recruiting

Loading map...

Research Team

J

Jazmin Y Camchong, PhD

CONTACT

L

Lamisa N Chowdhury, BS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

DEVICE_FEASIBILITY

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here